Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJAOA101 for Premature Ovarian Insufficiency
NCT05522634Phase 1Unknown
- Sponsor
- Tongji Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TJAOA101 in premature ovarian insufficiency (POI), sponsored by Tongji Hospital. Primary endpoints: Basal level of serum FSH at 6 months and Recovery rate of ovarian function at 6 months. Status: unknown.
02
Drugs
TJAOA101
03
Conditions
premature ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT05522634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522634.